RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-2.03%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.01B
AUM Growth
+$1.01B
(-33%)
Cap. Flow
-$433M
Cap. Flow
% of AUM
-42.73%
Top 10 Holdings %
Top 10 Hldgs %
28.64%
Holding
97
New
5
Increased
11
Reduced
69
Closed
8
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$19.9M |
| 2 |
BioNTech
BNTX
|
$14.5M |
| 3 |
Align Technology
ALGN
|
$6.54M |
| 4 |
Cytokinetics
CYTK
|
$5.34M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
$5.3M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$31.6M |
| 2 |
Elevance Health
ELV
|
$25.4M |
| 3 |
McKesson
MCK
|
$25.1M |
| 4 |
Johnson & Johnson
JNJ
|
$24.8M |
| 5 |
Pfizer
PFE
|
$24.7M |
Sector Composition
| 1 | Healthcare | 98.1% |
| 2 | Industrials | 1.09% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$657B
| $35.4M | 3.49% | 123,500 -46,500 | -27% | -$13.3M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $35.3M | 3.49% | 335,837 -89,163 | -21% | -$9.38M |
|
3
AbbVie
ABBV
$372B
| $31.6M | 3.12% | 195,000 -140,000 | -42% | -$22.7M |
|
|
4
UnitedHealth
UNH
$281B
| $29.6M | 2.92% | 58,000 -62,000 | -52% | -$31.6M |
|
|
5
McKesson
MCK
$85.4B
| $29.1M | 2.87% | 95,000 -82,000 | -46% | -$25.1M |
|
6
Jazz Pharmaceuticals
JAZZ
$7.75B
| $28.3M | 2.79% | 181,976 -108,024 | -37% | -$16.8M |
|
|
7
Pfizer
PFE
$141B
| $27.1M | 2.67% | 522,500 -477,500 | -48% | -$24.7M |
|
8
Cigna
CI
$80.3B
| $26.8M | 2.65% | 112,000 -28,000 | -20% | -$6.71M |
|
9
CVS Health
CVS
$92.8B
| $23.8M | 2.35% | 235,000 -175,000 | -43% | -$17.7M |
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $23.4M | 2.3% | 89,500 -75,500 | -46% | -$19.7M |
|
|
11
Elevance Health
ELV
$71.8B
| $22.7M | 2.24% | 46,199 -51,801 | -53% | -$25.4M |
|
12
Boston Scientific
BSX
$156B
| $22.6M | 2.23% | 510,000 -400,000 | -44% | -$17.7M |
|
|
ABMD
13
DELISTED
Abiomed Inc
ABMD
| $22.5M | 2.22% | 68,000 +16,000 | +31% | +$5.3M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $21.2M | 2.09% | 130,000 -45,000 | -26% | -$7.35M |
|
|
15
Johnson & Johnson
JNJ
$427B
| $20M | 1.98% | 113,000 -140,000 | -55% | -$24.8M |
|
|
16
Regeneron Pharmaceuticals
REGN
$61.5B
| $19.9M | 1.96% | +28,500 | New | +$19.9M |
|
17
Cooper Companies
COO
$13.4B
| $19.2M | 1.9% | 46,000 -8,260 | -15% | -$3.45M |
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $19.2M | 1.89% | 377,000 -53,000 | -12% | -$2.69M |
|
19
Merck
MRK
$210B
| $18.5M | 1.82% | 225,000 -75,000 | -25% | -$6.15M |
|
20
Medtronic
MDT
$119B
| $17.8M | 1.75% | 160,000 -136,000 | -46% | -$15.1M |
|
21
Tenet Healthcare
THC
$16.3B
| $17.5M | 1.72% | 203,000 -7,000 | -3% | -$602K |
|
|
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $17.1M | 1.69% | 280,000 -110,000 | -28% | -$6.73M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $17M | 1.67% | 220,000 -45,000 | -17% | -$3.47M |
|
24
Cencora
COR
$56.5B
| $16.7M | 1.65% | 108,000 -110,000 | -50% | -$17M |
|
|
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $16.1M | 1.59% | 136,000 -14,000 | -9% | -$1.66M |
|